Targeting neurotensin as a potential novel approach for the treatment of autism

The pathophysiology of autism remains obscure. Recently, serum neurotensin levels in children with autistic disorder have been found to be higher than those of normal children. Neurotensin is known to intensify neuronal NMDA-mediated glutamate signaling, which may cause apoptosis in autism. Further,...

Descripción completa

Detalles Bibliográficos
Autor principal: Ghanizadeh, Ahmad
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958902/
https://www.ncbi.nlm.nih.gov/pubmed/20920308
http://dx.doi.org/10.1186/1742-2094-7-58
_version_ 1782188392915664896
author Ghanizadeh, Ahmad
author_facet Ghanizadeh, Ahmad
author_sort Ghanizadeh, Ahmad
collection PubMed
description The pathophysiology of autism remains obscure. Recently, serum neurotensin levels in children with autistic disorder have been found to be higher than those of normal children. Neurotensin is known to intensify neuronal NMDA-mediated glutamate signaling, which may cause apoptosis in autism. Further, an imbalance of glutamate/GABAergic system in autism has been described. These observations lead to a postulate that neurotensin may accentuate the hyperglutaminergic state in autism, leading to apoptosis. Targeting neurotensin might be a possible novel approach for the treatment of autism.
format Text
id pubmed-2958902
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29589022010-10-22 Targeting neurotensin as a potential novel approach for the treatment of autism Ghanizadeh, Ahmad J Neuroinflammation Commentary The pathophysiology of autism remains obscure. Recently, serum neurotensin levels in children with autistic disorder have been found to be higher than those of normal children. Neurotensin is known to intensify neuronal NMDA-mediated glutamate signaling, which may cause apoptosis in autism. Further, an imbalance of glutamate/GABAergic system in autism has been described. These observations lead to a postulate that neurotensin may accentuate the hyperglutaminergic state in autism, leading to apoptosis. Targeting neurotensin might be a possible novel approach for the treatment of autism. BioMed Central 2010-10-01 /pmc/articles/PMC2958902/ /pubmed/20920308 http://dx.doi.org/10.1186/1742-2094-7-58 Text en Copyright ©2010 Ghanizadeh; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Ghanizadeh, Ahmad
Targeting neurotensin as a potential novel approach for the treatment of autism
title Targeting neurotensin as a potential novel approach for the treatment of autism
title_full Targeting neurotensin as a potential novel approach for the treatment of autism
title_fullStr Targeting neurotensin as a potential novel approach for the treatment of autism
title_full_unstemmed Targeting neurotensin as a potential novel approach for the treatment of autism
title_short Targeting neurotensin as a potential novel approach for the treatment of autism
title_sort targeting neurotensin as a potential novel approach for the treatment of autism
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958902/
https://www.ncbi.nlm.nih.gov/pubmed/20920308
http://dx.doi.org/10.1186/1742-2094-7-58
work_keys_str_mv AT ghanizadehahmad targetingneurotensinasapotentialnovelapproachforthetreatmentofautism

Ejemplares similares